FDA approves Faslodex as new therapy for breast cancer

     The Food and Drug Administration recently approved Faslodex to be used as a new therapy for advanced breast cancer in patients whose disease continues to progress after other treatments.  Faslodex was approved for use in post-menopausal women with hormone receptor positive metastatic breast cancer.  The drug is administered by injection once a month and should be made available for use by the end of May.

For more information visit the FDA's Web site at:  www.fda.gov/CDER/approval/f.htm - scroll down to Faslodex and click on the date 4/25/02.